A recent study, published in the Journal of the American Medical Association (JAMA) and presented at the Alzheimer’s Association International Conference (AAIC) in Amsterdam, reveals that the revolutionary Alzheimer’s drug, tested on 1,800 people, slows the disease by a minimum of 35 percent, making it the most effective dementia drug discovered thus far.
For those in the earliest stages of Alzheimer’s, donanemab reduces decline by an impressive 60 percent, with disease progression halted for at least a year in almost half of the trial participants.
According to Dr Liz Coulthard, associate professor in Dementia Neurology, at the University of Bristol, “Alzheimer’s is a common condition, and we want people to be eligible for treatment on the basis of need, rather than access being limited to those who can afford private care or live in certain areas of the country.”
USA Herald, Alzheimer’s drug, donanemab, dementia treatment, amyloid plaques, clinical symptoms, blood tests, early diagnosis, turning point, long-term condition, fulfilled lives, PET scanners, breakthrough, drug approval, FDA, MHRA, cost effectiveness, Alzheimer’s statistics, disease progression, NHS overhaul, treatment eligibility, research study, JAMA, AAIC
